Patents by Inventor Nicole Roth

Nicole Roth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240156946
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: December 21, 2021
    Publication date: May 16, 2024
    Applicants: CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nicole ROTH, Diego Chaves MORENO, Hans Wolfgang GROßE, Dominik VAHRENHORST, Susanne RAUCH
  • Patent number: 11918643
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: March 5, 2024
    Assignees: CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nicole Roth, Diego Chaves Moreno, Hans Wolfgang Große, Dominik Vahrenhorst, Susanne Rauch
  • Publication number: 20240066114
    Abstract: The present invention is inter alia directed to compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein selected or derived from a Coronavirus membrane protein (M), nucleocapsid protein (N), non-structural protein, and/or accessory protein or an immunogenic fragment or immunogenic variant thereof. The composition may additionally comprise at least one nucleic acid encoding at least one antigenic peptide or protein selected or derived from a Coronavirus spike protein (S). The nucleic acid sequences of the compositions are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The compositions provided herein are for use in treatment or prophylaxis of an infection with at least one Coronavirus, and may therefore be comprised in a vaccine, preferably a multivalent vaccine.
    Type: Application
    Filed: August 30, 2021
    Publication date: February 29, 2024
    Applicant: CureVac SE
    Inventors: Susanne RAUCH, Nicole ROTH, Benjamin PETSCH, Wolfgang GROSSE
  • Patent number: 11872280
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: May 31, 2022
    Date of Patent: January 16, 2024
    Assignees: CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nicole Roth, Diego Chaves Moreno, Hans Wolfgang Große, Dominik Vahrenhorst, Susanne Rauch
  • Publication number: 20230332011
    Abstract: Disclosed herein is a solvent-borne, two-pack coating composition. Further disclosed is a method of producing the coating composition, a method for coating and the coatings obtained therein, and the use of compounds (II) and (III) as corrosion inhibitors.
    Type: Application
    Filed: August 26, 2021
    Publication date: October 19, 2023
    Inventors: Patrick KEIL, Thorsten GELBRICH, Nicole ROTH, Silvia LENTER, Renate WEGNER, Sebastian POEHLKER
  • Publication number: 20220331422
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: May 31, 2022
    Publication date: October 20, 2022
    Applicants: CureVac AG, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nicole ROTH, Diego Chaves MORENO, Hans Wolfgang GROßE, Dominik VAHRENHORST, Susanne RAUCH
  • Publication number: 20220202930
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Application
    Filed: December 21, 2021
    Publication date: June 30, 2022
    Applicants: CureVac AG, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nicole ROTH, Diego Chaves MORENO, Hans Wolfgang GROSSE, Dominik VAHRENHORST, Susanne RAUCH
  • Publication number: 20220040281
    Abstract: The present invention is directed to a coding RNA for a Malaria vaccine. The coding RNA comprises at least one heterologous untranslated region (UTR), preferably a 3?-UTR and/or a 5?-UTR, and a coding region encoding at least one antigenic peptide or protein derived from a Malaria parasite, in particular at least one antigenic protein derived from circumsporozoite protein (CSP) of a Malaria parasite (e.g. Plasmodium falciparum). The present invention is also directed to compositions and vaccines comprising said coding RNA in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). Further, the invention concerns a kit, particularly a kit of parts comprising the coding RNA, or the composition, or the vaccine. The invention is also directed to a method of treating or preventing Malaria, and the first and second medical uses of the coding RNA, the composition, the vaccine, and the kit.
    Type: Application
    Filed: December 20, 2019
    Publication date: February 10, 2022
    Applicant: CureVac AG
    Inventors: Kim Ellen SCHWENDT, Benjamin PETSCH, Nicole ROTH
  • Publication number: 20160251542
    Abstract: The present invention relates to a use of an aqueous coating composition for applying a topcoat to at least one side of a substrate metal surface coated at least with a primer coat, said aqueous coating composition comprising at least one binder (A) in dispersion or solution in water, at least one crosslinking agent (B), at least one second binder (C) in dispersion or solution in water, and optionally at least one pigment (D), the second binder (C) being a copolymer which is obtainable by copolymerization of ethylenically unsaturated monomers in the presence of at least one polyurethane resin having polymerizable carbon double bonds; to a process for coating a substrate metal surface coated at least with a primer coat, said process comprising at least one step of at least single-sidedly applying the aqueous coating composition as topcoat to the substrate metal surface coated at least with a primer coat; and also to a coated substrate obtainable by this process.
    Type: Application
    Filed: September 4, 2014
    Publication date: September 1, 2016
    Applicant: BASF Coatings GmbH
    Inventors: Frank JOEGE, Nicole ROTH, Petra TOBOLL
  • Patent number: D464575
    Type: Grant
    Filed: January 24, 2002
    Date of Patent: October 22, 2002
    Inventors: Jean-Daniel Nicolas Roth, Nicole Roth